Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for AVT02 (biosimilar, adalimumab)

 Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for AVT02 (biosimilar, adalimumab)

Cipla Gulf Signs an Exclusive Commercialization Agreement with Alvotech for AVT02 (biosimilar, adalimumab)

Shots:

  • Alvotech will take care of development and supply of the product while Cipla Gulf, subsidiary of Cipla will be responsible for Alvotech’s AVT02 registration and commercialization
  • The agreement will allow Alvotech to have access for Cipla’s strong commercial network in selected emerging markets enabling patients with high-quality biosimilars
  • Alvotech’s AVT02 is a mAb and a biosimilar to AbbVie’s Humira involved in neutralizing TNF-α targeted for several autoimmune diseases including RA, AS, PP, Psoriatic Arthritis, UC, CD and is currently evaluated in P-III trial with its BLA submission with US FDA and EMA in H1’20

Click here to read full press release/ article | Ref: Cipla | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post